Regulatory publishing solution selected based on reliability and innovation
Nottingham, England and Morrisville, NC – 2021 年 10 月 25 日 – Calyx, the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that one of the world’s Top 10 pharmaceutical companies executed a contract to continue its use of the Calyx Regulatory Information Management (RIM) system for critical submissions of clinical development data to global regulators through 2026.
The Calyx RIM publishing module enables pharmaceutical companies to easily compile and submit comprehensive dossiers to global regulatory authorities. Designed by Calyx in-house regulatory experts, Calyx RIM is a proven, robust tool that optimizes the regulatory submission process and is continually updated to reflect worldwide health authorities’ evolving submission specifications.
The Top 10 pharmaceutical company made its selection based on decades of experience with the Calyx RIM solution and the trust that Calyx will continue to support submissions across the company’s complex global portfolio. The value of the RIM system is further increased through Calyx’s partnership with Microsoft and its use of innovative, cloud-based technology that keeps customers ahead of evolving regulatory requirements. Calyx RIM on Microsoft Azure provides tailored, direct delivery of system updates based on users’ needs and schedules, ensuring minimal disruption and ongoing compliance with global regulatory requirements.
“We value the trust this global pharmaceutical company has placed in Calyx and are delighted to extend our relationship as we support the important work they’re doing to bring new medical treatments and vaccines to patients around the world,” said John Blakeley, Chief Commercial Officer at Calyx.
Click here for more information on the benefits of the Calyx RIM system.
Through innovative eClinical and Regulatory solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market reliably. 凭借在临床开发方面的深厚专业知识以及在支持试验申办方和临床研究组织方面逾 25 年的经验，凯理斯利用其智慧和经验来解决复杂问题、提供快速见解并每天都将新药推向市场。
Christine Tobin | [电子邮件地址受保护] | +1 412-628-8598